Anavex Life Sciences Corp. (AVXL) Fundamentals

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2.
SHARE INFORMATION
Market Cap$ 824,634,983
Shares Outstanding77,942,815
Float75,782,139
Percent Float97.23%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 0
Latest Fiscal EPS$ -0.53
Latest Fiscal Date2021-09-30
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions300
Institutional Holdings Date2022-07-31
Institutional Bought Previous 3 Months4,508,522
Institutional Holdings Percent56.8%
Institutional Sold Previous 3 Months3,419,355
Insider Holdings Date2022-07-31
Insider Bought Previous 3 Months250,000
Insider Holdings Percent13.1
Insider Sold Previous 3 Months-
Insider Shares Owned10,162,410
TRADING INFO
52 Week High$ 23.73
52 Week Low$ 7.13
52 Week High Change$ -43.75
21 Day Moving Average$ 11.0143
21 Day Extended Moving Average$ 11.0957
50 Day Moving Average$ 10.599
50 Day Extended Moving Average$ 10.7817
200 Day Moving Average$ 12.8009
200 Day Extended Moving Average$ 11.9849
10 Day Average Volume769,730
20 Day Average Volume742,518
30 Day Average Volume812,752
50 Day Average Volume913,819
Alpha0.029295
Beta0.7906
Standard Deviation0.233348
R20.028713
7 Day Price Change$ -0.41
7 Day Percent Change-3.73%
21 Day Price Change$ -0.05
21 Day Percent Change-0.47%
30 Day Price Change$ -0.02
30 Day Percent Change-0.19%
Month to Date Price Change$ 0.32
Month to Date Percent Change3.12%
Quarter to Date Price Change$ 0.57
Quarter to Date Percent Change5.69%
180 Day Price Change$ -0.81
180 Day Percent Change-7.11%
200 Day Price Change$ -1.59
200 Day Percent Change-13.06%
Year to Date Price Change$ -6.76
Year to Date Percent Change-38.99%

Anavex Life Sciences Corp. (AVXL) Key Ratios

PROFITABILITY
EBIT Margin0.0%
EBITDA Margin0.0%
Pre-Tax Profit Margin0.0%
Profit Margin Count0.0%
Gross Margin0.0%
Profit Margin TOT0.0%
INCOME STATEMENTS
Revenue$ 0
Revenue Per Share$ 0.00
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book5.70
Total Debt To Equity0.00
Int Coverage0.00
Current Ratio16.90
Leverage Ratio1.10
Quick Ratio16.80
Long Term Debt To Capital0.00
VALUATION MEASURES
PE Ratio-18.70
Enterprise Value$ 708,848,181
Price to Sales0.00
Price to Free Cash-30.90
PE High Last 5 Years-10.50
Price To Book5.70
Price To Cash Flow0.00
PE Low Last 5 Years-8.80
Price to Tangible Book5.70
MANAGEMENT EFFECTIVENESS
Receivables Turnover0.00
Invoice Turnover0.00
Assets Turnover0.00
Return Assets-29.55
Return on Equity-31.36
Return on Capital-29.59

Anavex Life Sciences Corp. (AVXL) Profile

PROFILE INFO
Issue TypeCS
SEC TypeEQS
AuditorBDO USA, LLP
CEOChristopher U. Missling
Emplyoees25
Last AuditUQ
CIK0001314052
IndustryBiotechnology
SectorHealthcare
NAICSPharmaceutical Preparation Manufacturing(325412)
CONTACT INFO
Address51 West 52nd Street
7th Floor
New York, NY 10019
Websitehttps://www.anavex.com
Facsimile-
Telephone+1 844 689-3939
Emailir@anavex.com


Your Recent History
NASDAQ
AVXL
Anavex Lif..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.